SB 1281 Summary

• Moves pseudoephedrine from Schedule V to Schedule III of controlled dangerous substances, making it subject to stricter regulations.

• Removes the over-the-counter logbook requirements for pseudoephedrine sales (signature logs, identification records, and 9-gram monthly purchase limits).

• Exempts liquid, liquid capsule, and gel capsule formulations of pseudoephedrine when combined with other active ingredients from Schedule III classification.

• Eliminates reporting requirements for pharmacists on nonprescription pseudoephedrine sales to the central repository monitoring system.

• Effective date: November 1, 2012.